BayPine LP (“BayPine”), a private investment firm that drives digital transformation in market-leading businesses, announces that it has entered into a definitive agreement to acquire CenExel Clinical Research, Inc. (“CenExel” or the “Company”), a leading clinical trial site network focused on complex therapeutic areas. Following the closing of the transaction, BayPine will be the majority investor in CenExel alongside previous investor Webster Equity Partners (“Webster”), which will retain a minority stake, as well as Company management. With 18 locations geographically dispersed across major U.S. metro areas, CenExel is a trusted partner to leading biopharmaceutical sponsors.
Read the full article: BayPine to Acquire CenExel //
Source: https://www.businesswire.com/news/home/20250413774114/en/BayPine-to-Acquire-CenExel